查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1813939

肝纤维化生物标记市场规模、份额和趋势分析报告：按产品、技术、最终用途、地区和细分市场预测，2025-2033 年

Hepatic Fibrosis Biomarkers Market Size, Share & Trends Analysis Report By Product (Blood-based Kits, Saliva-based Kits), By Technology (Immunofiltration Assays, Lateral Flow Assays), By End Use, By Region, And Segment Forecasts, 2025 - 2033
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10个工作天内

价格

肝纤维化生物标记市场摘要

2024 年全球肝纤维化生物标记市场价值估计为 4.2351 亿美元，预计到 2033 年将达到 22.9173 亿美元，2025 年至 2033 年的复合年增长率为 20.01%。

由于肥胖、久坐的生活方式和METABOLIC INC.症候群导致 NASH 盛行率不断上升，人们对肝纤维化生物标记的兴趣日益浓厚。

根据美国国立糖尿病、消化和肾臟疾病研究所发表的一项研究，NAFLD 影响三分之一至三分之二的第 2 型糖尿病患者。其他研究也表明，超过 90% 的极度肥胖者和高达 75% 的超重者患有 NAFLD。推动 NASH特异性肝纤维化生物标记需求的主要因素之一是纤维化分期的临床意义。鑑于肝臟切片检查的风险和局限性，非侵入性生物标记为监测 NASH 患者的肝纤维化进展提供了一种更安全、更方便患者的治疗方法。

最新估计显示，全球约有3.3%的人口患有晚期肝纤维化，而使用振动控制瞬时弹性成像(VCTE)测量时，这一比例将上升至约3.5%。非酒精性脂肪肝病(NAFLD)，最近被重新定义为代谢功能障碍相关脂肪性肝病(MASLD)，影响着全球约25%的人口，由于肥胖和2型糖尿病发病率的上升，预计2016年至2019年期间某些地区的患病率将升至38%。

ELF、FIB-4、NAFLD 纤维化评分、APRI、FibroTest/FibroSure 等检测，以及 IGFBP7/SSc5D/Sema4D 等新兴多标誌物组合的采用，使得早期检测、准确分期以及减少对侵入性切片检查的依赖成为可能。这些进展，加上筛检力道的不断增加，使得肝纤维化生物标记成为应对全球肝病流行的核心工具。

肝纤维化的动态变化，特别是NASH等肝病的非侵入性生物标记物，为评估患者病情进展提供了新的工具。此类肝病指标可用于高风险患者临床试验中的患者风险分层和预后评估，从而提高成功率。这些循环生物标记还能提供肝纤维化动态变化的精确指标，并可用于衡量指定治疗的成败。 Nordic Bioscience的NASH专家可以检测一系列精确的肝纤维化生物标记物，包括PRO-C3 NASH生物标记物，以了解疾病的病程。

目录

第 1 章肝纤维化生物标记市场：调查方法与范围

2. 肝纤维化生物标记市场：执行摘要

  • 市场概述
  • 产品和技术概览
  • 最终用途简介
  • 竞争格局简介

3. 肝纤维化生物标记市场变数、趋势和范围

  • 市场区隔和范围
  • 市场体系展望
    • 母市场展望
    • 相关/辅助市场展望
  • 市场动态
  • 市场驱动因素分析
  • 市场限制因素分析
  • 波特五力分析
  • PESTLE分析
  • 管道分析

第四章肝纤维化生物标记市场：产品评估与趋势分析

  • 肝纤维化生物标记市场：产品差异分析
  • 套件和试剂
  • 侦测
  • 服务

第五章肝纤维化生物标记市场：技术评估与趋势分析

  • 肝纤维化生物标记市场：技术波动分析
  • 免疫检测
  • 分子诊断
  • 蛋白质体学/代谢体学
  • 基于影像的生物标记评估

第六章肝纤维化生物标记市场：最终用途估计和趋势分析

  • 肝纤维化生物标记市场：最终用途变异分析
  • 医院
  • 诊断实验室
  • 专科诊所
  • 学术研究机构
  • 製药和生物技术公司

7. 肝纤维化生物标记市场：区域业务分析

  • 区域市场概况
  • 北美洲
  • 欧洲
  • 亚太地区
  • 拉丁美洲
  • 中东和非洲

第八章 竞争态势

  • 公司分类
  • 战略地图
    • 新产品发布
    • 伙伴关係
    • 获得
    • 合作
    • 资金筹措
  • 2024年主要企业市占率分析
  • 公司热图分析
  • 公司简介
    • GENFIT
    • Prometheus Laboratories
    • Siemens Healthineers AG
    • BioPredictive
    • Quest Diagnostics
    • AstraZeneca
    • Exalenz Bioscience Ltd（meridian bioscience）
    • Labcorp
    • Pfizer Inc.
    • Bristol-Myers Squibb Company
Product Code: GVR-4-68040-714-2

Hepatic Fibrosis Biomarkers Market Summary

The global hepatic fibrosis biomarkers market size was estimated at USD 423.51 million in 2024 and is projected to reach USD 2,291.73 million by 2033, growing at a CAGR of 20.01% from 2025 to 2033. The rising prevalence of NASH, a consequence of obesity, sedentary lifestyles, and metabolic syndrome, has led to a greater focus on hepatic fibrosis biomarkers.

According to the study published in the National Institutes of Diabetes and Digestive and Kidney Diseases, NAFLD affects one-third to two-thirds of individuals with type 2 diabetes. Studies also indicate that over 90% of individuals with extreme obesity and up to 75% of overweight individuals have NAFLD. One of the key drivers propelling the demand for NASH-specific hepatic fibrosis biomarkers is the clinical significance of fibrosis staging. The risks and limitations associated with liver biopsies and non-invasive biomarkers offer a safer and more patient-friendly approach to monitoring hepatic fibrosis progression in NASH patients.

As of the most recent estimates, approximately 3.3% of the global population is living with advanced hepatic fibrosis, with rates rising to around 3.5% when measured using vibration-controlled transient elastography (VCTE). Non-alcoholic fatty liver disease (NAFLD), recently redefined as metabolic dysfunction-associated steatotic liver disease (MASLD), affects about 25% of the world's population, with prevalence increasing to 38% in certain regions between 2016 and 2019 due to rising obesity and type 2 diabetes rates.

The adoption of tests such as ELF, FIB-4, NAFLD fibrosis score, APRI, and FibroTest/FibroSure, alongside emerging multi-marker panels like IGFBP7/SSc5D/Sema4D, is enabling earlier detection, accurate staging, and reduced reliance on invasive liver biopsies. These advancements, combined with rising screening initiatives, are positioning hepatic fibrosis biomarkers as a central tool in tackling the global liver disease epidemic.

The dynamics of liver fibrosis are specifically targeted by noninvasive biomarkers of liver condition, such as NASH, which offer a novel tool to assess a patient's disease progression. Such indicators for liver illness could be applied to patient risk classification as well as prognostic enrichment of clinical trials aimed at the individuals with the highest risk, improving the likelihood of success. These blood biomarkers are also accurate indicators of the dynamics of liver fibrosis and can be used to gauge the success of a given treatment. Nordic Bioscience NASH specialists can examine a precise panel of liver fibrosis biomarkers, including the biomarker PRO-C3 NASH, which offers insight into the course of the illness.

Global Hepatic Fibrosis Biomarkers Market Report Segmentation

This report forecasts revenue growth and provides an analysis of the latest trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global hepatic fibrosis biomarkers market report based on product, technology, end use, and region:

  • Product Outlook (Revenue, USD Million, 2021 - 2033)
  • Kits and Reagents
  • Assays
  • Services
  • Technology Outlook (Revenue, USD Million, 2021 - 2033)
  • Immunoassay
  • Molecular Diagnostics
  • Proteomics/Metabolomics
  • Imaging-based Biomarker Assessment
  • End Use Outlook (Revenue, USD Million, 2021 - 2033)
  • Hospitals
  • Diagnostic Laboratories
  • Specialty Clinics
  • Academic & Research Institutes
  • Pharmaceutical & Biotechnology Companies
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Hepatic Fibrosis Biomarkers Market: Methodology and Scope

  • 1.1. Market Segmentation and Scope
    • 1.1.1. Segment Definitions
      • 1.1.1.1. Product Segment
      • 1.1.1.2. Technology Segment
      • 1.1.1.3. Sample Product segment
      • 1.1.1.4. End Use Segment
  • 1.2. Regional Scope
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Objectives
    • 1.4.1. Objective - 1
    • 1.4.2. Objective - 2
    • 1.4.3. Objective - 3
  • 1.5. Research Methodology
  • 1.6. Information Procurement
    • 1.6.1. Purchased Database
    • 1.6.2. GVR's Internal Database
    • 1.6.3. Secondary Sources
    • 1.6.4. Primary Research
  • 1.7. Information or Data Analysis
    • 1.7.1. Data Analysis Models
  • 1.8. Market Formulation & Validation
  • 1.9. Model Details
    • 1.9.1. Commodity Flow Analysis
  • 1.10. List of Secondary Sources
  • 1.11. List of Abbreviations

Chapter 2. Hepatic Fibrosis Biomarkers Market: Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Product and Technology Snapshot
  • 2.3. End Use Snapshot
  • 2.4. Competitive Landscape Snapshot

Chapter 3. Hepatic Fibrosis Biomarkers Market Variables, Trends, & Scope

  • 3.1. Market Segmentation and Scope
  • 3.2. Market Lineage Outlook
    • 3.2.1. Parent Market Outlook
    • 3.2.2. Related/Ancillary Market Outlook
  • 3.3. Market Dynamics
  • 3.4. Market Drivers Analysis
  • 3.5. Market Restraint Analysis
  • 3.6. Porter's Five Forces Analysis
  • 3.7. PESTLE Analysis
  • 3.8. Pipeline Analysis

Chapter 4. Hepatic Fibrosis Biomarkers Market: Product Estimates & Trend Analysis

  • 4.1. Hepatic Fibrosis Biomarkers Market: Product Movement Analysis
  • 4.2. Kits and Reagents
    • 4.2.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.3. Assays
    • 4.3.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.4. Services
    • 4.4.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. Hepatic Fibrosis Biomarkers Market: Technology Estimates & Trend Analysis

  • 5.1. Hepatic Fibrosis Biomarkers Market: Technology Movement Analysis
  • 5.2. Immunoassays
    • 5.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.3. Molecular Diagnostics
    • 5.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.4. Proteomics/Metabolomics
    • 5.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.5. Imaging-based Biomarker Assessment
    • 5.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Hepatic Fibrosis Biomarkers Market: End Use Estimates & Trend Analysis

  • 6.1. Hepatic Fibrosis Biomarkers Market: End Use Movement Analysis
  • 6.2. Hospitals
    • 6.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.3. Diagnostics Laboratories
    • 6.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.4. Specialty Clinics
    • 6.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5. Academic & Research Institutes
    • 6.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.6. Pharmaceutical & Biotechnology Companies
    • 6.6.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Hepatic Fibrosis Biomarkers Market: Regional Business Analysis

  • 7.1. Regional Market Snapshot
  • 7.2. North America
    • 7.2.1. North America Hepatic Fibrosis Biomarkers Market Estimates And Forecast, 2021 - 2033 (USD Million)
    • 7.2.2. U.S.
      • 7.2.2.1. U.S. Hepatic Fibrosis Biomarkers Market, 2021 - 2033 (USD Million)
      • 7.2.2.2. Key Country Dynamics
      • 7.2.2.3. Regulatory Framework
      • 7.2.2.4. Reimbursement Scenario
      • 7.2.2.5. Competitive Scenario
    • 7.2.3. Canada
      • 7.2.3.1. Canada Hepatic Fibrosis Biomarkers Market, 2021 - 2033 (USD Million)
      • 7.2.3.2. Key Country Dynamics
      • 7.2.3.3. Regulatory Framework
      • 7.2.3.4. Reimbursement Scenario
      • 7.2.3.5. Competitive Scenario
    • 7.2.4. Mexico
      • 7.2.4.1. Mexico Hepatic Fibrosis Biomarkers Market, 2021 - 2033 (USD Million)
      • 7.2.4.2. Key Country Dynamics
      • 7.2.4.3. Regulatory Framework
      • 7.2.4.4. Reimbursement Scenario
      • 7.2.4.5. Competitive Scenario
  • 7.3. Europe
    • 7.3.1. Europe Hepatic Fibrosis Biomarkers Market, 2021 - 2033 (USD Million)
    • 7.3.2. UK
      • 7.3.2.1. UK Hepatic Fibrosis Biomarkers Market, 2021 - 2033 (USD Million)
      • 7.3.2.2. Key Country Dynamics
      • 7.3.2.3. Regulatory Framework
      • 7.3.2.4. Reimbursement Scenario
      • 7.3.2.5. Competitive Scenario
    • 7.3.3. Germany
      • 7.3.3.1. Germany Hepatic Fibrosis Biomarkers Market, 2021 - 2033 (USD Million)
      • 7.3.3.2. Key Country Dynamics
      • 7.3.3.3. Regulatory Framework
      • 7.3.3.4. Reimbursement Scenario
      • 7.3.3.5. Competitive Scenario
    • 7.3.4. Spain
      • 7.3.4.1. Spain Hepatic Fibrosis Biomarkers Market, 2021 - 2033 (USD Million)
      • 7.3.4.2. Key Country Dynamics
      • 7.3.4.3. Regulatory Framework
      • 7.3.4.4. Reimbursement Scenario
      • 7.3.4.5. Competitive Scenario
    • 7.3.5. France
      • 7.3.5.1. France Hepatic Fibrosis Biomarkers Market, 2021 - 2033 (USD Million)
      • 7.3.5.2. Key Country Dynamics
      • 7.3.5.3. Regulatory Framework
      • 7.3.5.4. Reimbursement Scenario
      • 7.3.5.5. Competitive Scenario
    • 7.3.6. Italy
      • 7.3.6.1. Italy Hepatic Fibrosis Biomarkers Market, 2021 - 2033 (USD Million)
      • 7.3.6.2. Key Country Dynamics
      • 7.3.6.3. Regulatory Framework
      • 7.3.6.4. Reimbursement Scenario
      • 7.3.6.5. Competitive Scenario
    • 7.3.7. Denmark
      • 7.3.7.1. Denmark Hepatic Fibrosis Biomarkers Market, 2021 - 2033 (USD Million)
      • 7.3.7.2. Key Country Dynamics
      • 7.3.7.3. Regulatory Framework
      • 7.3.7.4. Reimbursement Scenario
      • 7.3.7.5. Competitive Scenario
    • 7.3.8. Sweden
      • 7.3.8.1. Sweden Hepatic Fibrosis Biomarkers Market, 2021 - 2033 (USD Million)
      • 7.3.8.2. Key Country Dynamics
      • 7.3.8.3. Regulatory Framework
      • 7.3.8.4. Reimbursement Scenario
      • 7.3.8.5. Competitive Scenario
    • 7.3.9. Norway
      • 7.3.9.1. Norway Hepatic Fibrosis Biomarkers Market, 2021 - 2033 (USD Million)
      • 7.3.9.2. Key Country Dynamics
      • 7.3.9.3. Regulatory Framework
      • 7.3.9.4. Reimbursement Scenario
      • 7.3.9.5. Competitive Scenario
  • 7.4. Asia Pacific
    • 7.4.1. Asia-Pacific Hepatic Fibrosis Biomarkers Market, 2021 - 2033 (USD Million)
    • 7.4.2. Japan
      • 7.4.2.1. Japan Hepatic Fibrosis Biomarkers Market, 2021 - 2033 (USD Million)
      • 7.4.2.2. Key Country Dynamics
      • 7.4.2.3. Regulatory Framework
      • 7.4.2.4. Reimbursement Scenario
      • 7.4.2.5. Competitive Scenario
    • 7.4.3. China
      • 7.4.3.1. China Hepatic Fibrosis Biomarkers Market, 2021 - 2033 (USD Million)
      • 7.4.3.2. Key Country Dynamics
      • 7.4.3.3. Regulatory Framework
      • 7.4.3.4. Reimbursement Scenario
      • 7.4.3.5. Competitive Scenario
    • 7.4.4. India
      • 7.4.4.1. India Hepatic Fibrosis Biomarkers Market, 2021 - 2033 (USD Million)
      • 7.4.4.2. Key Country Dynamics
      • 7.4.4.3. Regulatory Framework
      • 7.4.4.4. Reimbursement Scenario
      • 7.4.4.5. Competitive Scenario
    • 7.4.5. South Korea
      • 7.4.5.1. South Korea Hepatic Fibrosis Biomarkers Market, 2021 - 2033 (USD Million)
      • 7.4.5.2. Key Country Dynamics
      • 7.4.5.3. Regulatory Framework
      • 7.4.5.4. Reimbursement Scenario
      • 7.4.5.5. Competitive Scenario
    • 7.4.6. Thailand
      • 7.4.6.1. Thailand Hepatic Fibrosis Biomarkers Market, 2021 - 2033 (USD Million)
      • 7.4.6.2. Key Country Dynamics
      • 7.4.6.3. Regulatory Framework
      • 7.4.6.4. Reimbursement Scenario
      • 7.4.6.5. Competitive Scenario
    • 7.4.7. Australia
      • 7.4.7.1. Australia Hepatic Fibrosis Biomarkers Market, 2021 - 2033 (USD Million)
      • 7.4.7.2. Key Country Dynamics
      • 7.4.7.3. Regulatory Framework
      • 7.4.7.4. Reimbursement Scenario
      • 7.4.7.5. Competitive Scenario
  • 7.5. Latin America
    • 7.5.1. Latin America Hepatic Fibrosis Biomarkers Market, 2021 - 2033 (USD Million)
    • 7.5.2. Brazil
      • 7.5.2.1. Brazil Hepatic Fibrosis Biomarkers Market, 2021 - 2033 (USD Million)
      • 7.5.2.2. Key Country Dynamics
      • 7.5.2.3. Regulatory Framework
      • 7.5.2.4. Reimbursement Scenario
      • 7.5.2.5. Competitive Scenario
    • 7.5.3. Argentina
      • 7.5.3.1. Argentina Hepatic Fibrosis Biomarkers Market, 2021 - 2033 (USD Million)
      • 7.5.3.2. Key Country Dynamics
      • 7.5.3.3. Regulatory Framework
      • 7.5.3.4. Reimbursement Scenario
      • 7.5.3.5. Competitive Scenario
  • 7.6. MEA
    • 7.6.1. MEA Hepatic Fibrosis Biomarkers Market, 2021 - 2033 (USD Million)
    • 7.6.2. South Africa
      • 7.6.2.1. South Africa Hepatic Fibrosis Biomarkers Market, 2021 - 2033 (USD Million)
      • 7.6.2.2. Key Country Dynamics
      • 7.6.2.3. Regulatory Framework
      • 7.6.2.4. Reimbursement Scenario
      • 7.6.2.5. Competitive Scenario
    • 7.6.3. Saudi Arabia
      • 7.6.3.1. Saudi Arabia Hepatic Fibrosis Biomarkers Market, 2021 - 2033 (USD Million)
      • 7.6.3.2. Key Country Dynamics
      • 7.6.3.3. Regulatory Framework
      • 7.6.3.4. Reimbursement Scenario
      • 7.6.3.5. Competitive Scenario
    • 7.6.4. UAE
      • 7.6.4.1. UAE Hepatic Fibrosis Biomarkers Market, 2021 - 2033 (USD Million)
      • 7.6.4.2. Key Country Dynamics
      • 7.6.4.3. Regulatory Framework
      • 7.6.4.4. Reimbursement Scenario
      • 7.6.4.5. Competitive Scenario
    • 7.6.5. Kuwait
      • 7.6.5.1. Kuwait Hepatic Fibrosis Biomarkers Market, 2021 - 2033 (USD Million)
      • 7.6.5.2. Key Country Dynamics
      • 7.6.5.3. Regulatory Framework
      • 7.6.5.4. Reimbursement Scenario
      • 7.6.5.5. Competitive Scenario

Chapter 8. Competitive Landscape

  • 8.1. Company Categorization
  • 8.2. Strategy Mapping
    • 8.2.1. New Product Launch
    • 8.2.2. Partnerships
    • 8.2.3. Acquisition
    • 8.2.4. Collaboration
    • 8.2.5. Funding
  • 8.3. Key Company Market Share Analysis, 2024
  • 8.4. Company Heat Map Analysis
  • 8.5. Company Profiles
    • 8.5.1. GENFIT
      • 8.5.1.1. Company Overview
      • 8.5.1.2. Financial Performance
      • 8.5.1.3. Product Benchmarking
      • 8.5.1.4. Strategic Initiatives
    • 8.5.2. Prometheus Laboratories
      • 8.5.2.1. Company Overview
      • 8.5.2.2. Financial Performance
      • 8.5.2.3. Product Benchmarking
      • 8.5.2.4. Strategic Initiatives
    • 8.5.3. Siemens Healthineers AG
      • 8.5.3.1. Company Overview
      • 8.5.3.2. Financial Performance
      • 8.5.3.3. Product Benchmarking
      • 8.5.3.4. Strategic Initiatives
    • 8.5.4. BioPredictive
      • 8.5.4.1. Company Overview
      • 8.5.4.2. Financial Performance
      • 8.5.4.3. Product Benchmarking
      • 8.5.4.4. Strategic Initiatives
    • 8.5.5. Quest Diagnostics
      • 8.5.5.1. Company Overview
      • 8.5.5.2. Financial Performance
      • 8.5.5.3. Product Benchmarking
      • 8.5.5.4. Strategic Initiatives
    • 8.5.6. AstraZeneca
      • 8.5.6.1. Company Overview
      • 8.5.6.2. Financial Performance
      • 8.5.6.3. Product Benchmarking
      • 8.5.6.4. Strategic Initiatives
    • 8.5.7. Exalenz Bioscience Ltd (meridian bioscience)
      • 8.5.7.1. Company Overview
      • 8.5.7.2. Financial Performance
      • 8.5.7.3. Product Benchmarking
      • 8.5.7.4. Strategic Initiatives
    • 8.5.8. Labcorp
      • 8.5.8.1. Company Overview
      • 8.5.8.2. Financial Performance
      • 8.5.8.3. Product Benchmarking
      • 8.5.8.4. Strategic Initiatives
    • 8.5.9. Pfizer Inc.
      • 8.5.9.1. Company Overview
      • 8.5.9.2. Financial Performance
      • 8.5.9.3. Product Benchmarking
      • 8.5.9.4. Strategic Initiatives
    • 8.5.10. Bristol-Myers Squibb Company
      • 8.5.10.1. Company Overview
      • 8.5.10.2. Financial Performance
      • 8.5.10.3. Product Benchmarking
      • 8.5.10.4. Strategic Initiatives

List of Tables

  • Table 1 List Of Secondary Sources
  • Table 2 List Of Abbreviation
  • Table 3 Global Hepatic Fibrosis Biomarkers Market, By Region, 2021 - 2033 (USD Million)
  • Table 4 Global Hepatic Fibrosis Biomarkers Market, By Product, 2021 - 2033 (USD Million)
  • Table 5 Global Hepatic Fibrosis Biomarkers Market, By Technology, 2021 - 2033 (USD Million)
  • Table 6 Global Hepatic Fibrosis Biomarkers Market, By End Use, 2021 - 2033 (USD Million)
  • Table 7 North America Hepatic Fibrosis Biomarkers Market, By Country, 2021 - 2033 (USD Million)
  • Table 8 North America Hepatic Fibrosis Biomarkers Market, By Product, 2021 - 2033 (USD Million)
  • Table 9 North America Hepatic Fibrosis Biomarkers Market, By Technology, 2021 - 2033 (USD Million)
  • Table 10 North America Hepatic Fibrosis Biomarkers Market, By End Use, 2021 - 2033 (USD Million)
  • Table 11 U.S. Hepatic Fibrosis Biomarkers Market, By Product, 2021 - 2033 (USD Million)
  • Table 12 U.S. Hepatic Fibrosis Biomarkers Market, By Technology, 2021 - 2033 (USD Million)
  • Table 13 U.S. Hepatic Fibrosis Biomarkers Market, By End Use, 2021 - 2033 (USD Million)
  • Table 14 Canada Hepatic Fibrosis Biomarkers Market, By Product, 2021 - 2033 (USD Million)
  • Table 15 Canada Hepatic Fibrosis Biomarkers Market, By Technology, 2021 - 2033 (USD Million)
  • Table 16 Canada Hepatic Fibrosis Biomarkers Market, By End Use, 2021 - 2033 (USD Million)
  • Table 17 Mexico Hepatic Fibrosis Biomarkers Market, By Product, 2021 - 2033 (USD Million)
  • Table 18 Mexico Hepatic Fibrosis Biomarkers Market, By Technology, 2021 - 2033 (USD Million)
  • Table 19 Mexico Hepatic Fibrosis Biomarkers Market, By End Use, 2021 - 2033 (USD Million)
  • Table 20 Europe Hepatic Fibrosis Biomarkers Market, By Country, 2021 - 2033 (USD Million)
  • Table 21 Europe Hepatic Fibrosis Biomarkers Market, By Product, 2021 - 2033 (USD Million)
  • Table 22 Europe Hepatic Fibrosis Biomarkers Market, By Technology, 2021 - 2033 (USD Million)
  • Table 23 Europe Hepatic Fibrosis Biomarkers Market, By End Use, 2021 - 2033 (USD Million)
  • Table 24 UK Hepatic Fibrosis Biomarkers Market, By Product, 2021 - 2033 (USD Million)
  • Table 25 UK Hepatic Fibrosis Biomarkers Market, By Technology, 2021 - 2033 (USD Million)
  • Table 26 UK Hepatic Fibrosis Biomarkers Market, By End Use, 2021 - 2033 (USD Million)
  • Table 27 Germany Hepatic Fibrosis Biomarkers Market, By Product, 2021 - 2033 (USD Million)
  • Table 28 Germany Hepatic Fibrosis Biomarkers Market, By Technology, 2021 - 2033 (USD Million)
  • Table 29 Germany Hepatic Fibrosis Biomarkers Market, By End Use, 2021 - 2033 (USD Million)
  • Table 30 France Hepatic Fibrosis Biomarkers Market, By Product, 2021 - 2033 (USD Million)
  • Table 31 France Hepatic Fibrosis Biomarkers Market, By Technology, 2021 - 2033 (USD Million)
  • Table 32 France Hepatic Fibrosis Biomarkers Market, By End Use, 2021 - 2033 (USD Million)
  • Table 33 Italy Hepatic Fibrosis Biomarkers Market, By Product, 2021 - 2033 (USD Million)
  • Table 34 Italy Hepatic Fibrosis Biomarkers Market, By Technology, 2021 - 2033 (USD Million)
  • Table 35 Italy Hepatic Fibrosis Biomarkers Market, By End Use, 2021 - 2033 (USD Million)
  • Table 36 Spain Hepatic Fibrosis Biomarkers Market, By Product, 2021 - 2033 (USD Million)
  • Table 37 Spain Hepatic Fibrosis Biomarkers Market, By Technology, 2021 - 2033 (USD Million)
  • Table 38 Spain Hepatic Fibrosis Biomarkers Market, By End Use, 2021 - 2033 (USD Million)
  • Table 39 Sweden Hepatic Fibrosis Biomarkers Market, By Product, 2021 - 2033 (USD Million)
  • Table 40 Sweden Hepatic Fibrosis Biomarkers Market, By Technology, 2021 - 2033 (USD Million)
  • Table 41 Sweden Hepatic Fibrosis Biomarkers Market, By End Use, 2021 - 2033 (USD Million)
  • Table 42 Norway Hepatic Fibrosis Biomarkers Market, By Product, 2021 - 2033 (USD Million)
  • Table 43 Norway Hepatic Fibrosis Biomarkers Market, By Technology, 2021 - 2033 (USD Million)
  • Table 44 Norway Hepatic Fibrosis Biomarkers Market, By End Use, 2021 - 2033 (USD Million)
  • Table 45 Denmark Hepatic Fibrosis Biomarkers Market, By Product, 2021 - 2033 (USD Million)
  • Table 46 Denmark Hepatic Fibrosis Biomarkers Market, By Technology, 2021 - 2033 (USD Million)
  • Table 47 Denmark Hepatic Fibrosis Biomarkers Market, By End Use, 2021 - 2033 (USD Million)
  • Table 48 Asia Pacific Hepatic Fibrosis Biomarkers Market, By Country, 2021 - 2033 (USD Million)
  • Table 49 Asia Pacific Hepatic Fibrosis Biomarkers Market, By Product, 2021 - 2033 (USD Million)
  • Table 50 Asia Pacific Hepatic Fibrosis Biomarkers Market, By Technology, 2021 - 2033 (USD Million)
  • Table 51 Asia Pacific Hepatic Fibrosis Biomarkers Market, By End Use, 2021 - 2033 (USD Million)
  • Table 52 Japan Hepatic Fibrosis Biomarkers Market, By Product, 2021 - 2033 (USD Million)
  • Table 53 Japan Hepatic Fibrosis Biomarkers Market, By Technology, 2021 - 2033 (USD Million)
  • Table 54 Japan Hepatic Fibrosis Biomarkers Market, By End Use, 2021 - 2033 (USD Million)
  • Table 55 China Hepatic Fibrosis Biomarkers Market, By Product, 2021 - 2033 (USD Million)
  • Table 56 China Hepatic Fibrosis Biomarkers Market, By Technology, 2021 - 2033 (USD Million)
  • Table 57 China Hepatic Fibrosis Biomarkers Market, By End Use, 2021 - 2033 (USD Million)
  • Table 58 India Hepatic Fibrosis Biomarkers Market, By Product, 2021 - 2033 (USD Million)
  • Table 59 India Hepatic Fibrosis Biomarkers Market, By Technology, 2021 - 2033 (USD Million)
  • Table 60 India Hepatic Fibrosis Biomarkers Market, By End Use, 2021 - 2033 (USD Million)
  • Table 61 Australia Hepatic Fibrosis Biomarkers Market, By Product, 2021 - 2033 (USD Million)
  • Table 62 Australia Hepatic Fibrosis Biomarkers Market, By Technology, 2021 - 2033 (USD Million)
  • Table 63 Australia Hepatic Fibrosis Biomarkers Market, By End Use, 2021 - 2033 (USD Million)
  • Table 64 Thailand Hepatic Fibrosis Biomarkers Market, By Product, 2021 - 2033 (USD Million)
  • Table 65 Thailand Hepatic Fibrosis Biomarkers Market, By Technology, 2021 - 2033 (USD Million)
  • Table 66 Thailand Hepatic Fibrosis Biomarkers Market, By End Use, 2021 - 2033 (USD Million)
  • Table 67 South Korea Hepatic Fibrosis Biomarkers Market, By Product, 2021 - 2033 (USD Million)
  • Table 68 South Korea Hepatic Fibrosis Biomarkers Market, By Technology, 2021 - 2033 (USD Million)
  • Table 69 South Korea Hepatic Fibrosis Biomarkers Market, By End Use, 2021 - 2033 (USD Million)
  • Table 70 Latin America Hepatic Fibrosis Biomarkers Market, By Country, 2021 - 2033 (USD Million)
  • Table 71 Latin America Hepatic Fibrosis Biomarkers Market, By Product, 2021 - 2033 (USD Million)
  • Table 72 Latin America Hepatic Fibrosis Biomarkers Market, By Technology, 2021 - 2033 (USD Million)
  • Table 73 Latin America Hepatic Fibrosis Biomarkers Market, By End Use, 2021 - 2033 (USD Million)
  • Table 74 Brazil Hepatic Fibrosis Biomarkers Market, By Product, 2021 - 2033 (USD Million)
  • Table 75 Brazil Hepatic Fibrosis Biomarkers Market, By Technology, 2021 - 2033 (USD Million)
  • Table 76 Brazil Hepatic Fibrosis Biomarkers Market, By End Use, 2021 - 2033 (USD Million)
  • Table 77 Argentina Hepatic Fibrosis Biomarkers Market, By Product, 2021 - 2033 (USD Million)
  • Table 78 Argentina Hepatic Fibrosis Biomarkers Market, By Technology, 2021 - 2033 (USD Million)
  • Table 79 Argentina Hepatic Fibrosis Biomarkers Market, By End Use, 2021 - 2033 (USD Million)
  • Table 80 MEA Hepatic Fibrosis Biomarkers Market, By Country, 2021 - 2033 (USD Million)
  • Table 81 MEA Hepatic Fibrosis Biomarkers Market, By Product, 2021 - 2033 (USD Million)
  • Table 82 MEA Hepatic Fibrosis Biomarkers Market, By Technology, 2021 - 2033 (USD Million)
  • Table 83 MEA Hepatic Fibrosis Biomarkers Market, By End Use, 2021 - 2033 (USD Million)
  • Table 84 South Africa Hepatic Fibrosis Biomarkers Market, By Product, 2021 - 2033 (USD Million)
  • Table 85 South Africa Hepatic Fibrosis Biomarkers Market, By Technology, 2021 - 2033 (USD Million)
  • Table 86 South Africa Hepatic Fibrosis Biomarkers Market, By End Use, 2021 - 2033 (USD Million)
  • Table 87 Saudi Arabia Hepatic Fibrosis Biomarkers Market, By Product, 2021 - 2033 (USD Million)
  • Table 88 Saudi Arabia Hepatic Fibrosis Biomarkers Market, By Technology, 2021 - 2033 (USD Million)
  • Table 89 Saudi Arabia Hepatic Fibrosis Biomarkers Market, By End Use, 2021 - 2033 (USD Million)
  • Table 90 UAE Hepatic Fibrosis Biomarkers Market, By Product, 2021 - 2033 (USD Million)
  • Table 91 UAE Hepatic Fibrosis Biomarkers Market, By Technology, 2021 - 2033 (USD Million)
  • Table 92 UAE Hepatic Fibrosis Biomarkers Market, By End Use, 2021 - 2033 (USD Million)
  • Table 93 Kuwait Hepatic Fibrosis Biomarkers Market, By Product, 2021 - 2033 (USD Million)
  • Table 94 Kuwait Hepatic Fibrosis Biomarkers Market, By Technology, 2021 - 2033 (USD Million)
  • Table 95 Kuwait Hepatic Fibrosis Biomarkers Market, By End Use, 32021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Information procurement
  • Fig. 3 Market summary
  • Fig. 4 Market segmentation & scope
  • Fig. 5 Market size and growth prospects
  • Fig. 6 Global Hepatic fibrosis biomarkers market- Key market driver analysis
  • Fig. 7 Global Hepatic fibrosis biomarkers market - Key market restraint analysis
  • Fig. 8 Penetration & growth prospect mapping
  • Fig. 9 Global Hepatic fibrosis biomarkers market - Porter's analysis
  • Fig. 10 Global Hepatic fibrosis biomarkers market - PESTEL analysis
  • Fig. 11 Global Hepatic fibrosis biomarkers market Product outlook key takeaways
  • Fig. 12 Global Hepatic fibrosis biomarkers market: Product movement analysis
  • Fig. 13 Kits and reagents market estimates, 2021 - 2033 (USD Million)
  • Fig. 14 Reagents market estimates, 2021 - 2033 (USD Million)
  • Fig. 15 Services market estimates, 2021 - 2033 (USD Million)
  • Fig. 16 Global Hepatic fibrosis biomarkers market technology outlook key takeaways
  • Fig. 17 Global Hepatic fibrosis biomarkers market: technology movement analysis
  • Fig. 18 Immunoassays market estimates, 2021 - 2033 (USD Million)
  • Fig. 19 Molecular diagnostics market estimates, 2021 - 2033 (USD Million)
  • Fig. 20 Proteomics/metabolomics market estimates, 2021 - 2033 (USD Million)
  • Fig. 21 Imaging-based biomarker assessment market estimates, 2021 - 2033 (USD Million)
  • Fig. 22 Global Hepatic fibrosis biomarkers market end use outlook key takeaways
  • Fig. 23 Global Hepatic fibrosis biomarkers market: end use movement analysis
  • Fig. 24 Retail and online pharmacies market estimates, 2021 - 2033 (USD Million)
  • Fig. 25 Hospitals and diagnostics laboratories market estimates, 2021 - 2033 (USD Million)
  • Fig. 26 NGO/Community-based distribution market estimates, 2021 - 2033 (USD Million)
  • Fig. 27 Regional marketplace: Key takeaways
  • Fig. 28 Global Hepatic Fibrosis Biomarkers market: Regional movement analysis
  • Fig. 29 North America Hepatic Fibrosis Biomarkers market, 2021 - 2033 (USD Million)
  • Fig. 30 U.S. Hepatic fibrosis biomarkers market, 2021 - 2033 (USD Million)
  • Fig. 31 Canada Hepatic fibrosis biomarkers market, 2021 - 2033 (USD Million)
  • Fig. 32 Mexico Hepatic fibrosis biomarkers market, 2021 - 2033 (USD Million)
  • Fig. 33 Europe Hepatic fibrosis biomarkers market, 2021 - 2033 (USD Million)
  • Fig. 34 UK Hepatic fibrosis biomarkers market, 2021 - 2033 (USD Million)
  • Fig. 35 Germany Hepatic fibrosis biomarkers market, 2021 - 2033 (USD Million)
  • Fig. 36 France Hepatic fibrosis biomarkers market, 2021 - 2033 (USD Million)
  • Fig. 37 Spain Hepatic fibrosis biomarkers market, 2021 - 2033 (USD Million)
  • Fig. 38 Italy Hepatic fibrosis biomarkers market, 2021 - 2033 (USD Million)
  • Fig. 39 Denmark Hepatic fibrosis biomarkers market, 2021 - 2033 (USD Million)
  • Fig. 40 Sweden Hepatic fibrosis biomarkers market, 2021 - 2033 (USD Million)
  • Fig. 41 Norway Hepatic fibrosis biomarkers market, 2021 - 2033 (USD Million)
  • Fig. 42 Asia Pacific Hepatic fibrosis biomarkers market, 2021 - 2033 (USD Million)
  • Fig. 43 Japan Hepatic fibrosis biomarkers market, 2021 - 2033 (USD Million)
  • Fig. 44 China Hepatic fibrosis biomarkers market, 2021 - 2033 (USD Million)
  • Fig. 45 India Hepatic fibrosis biomarkers market, 2021 - 2033 (USD Million)
  • Fig. 46 South Korea Hepatic fibrosis biomarkers market, 2021 - 2033 (USD Million)
  • Fig. 47 Australia Hepatic fibrosis biomarkers market, 2021 - 2033 (USD Million)
  • Fig. 48 Thailand Hepatic fibrosis biomarkers market, 2021 - 2033 (USD Million)
  • Fig. 49 Latin America Hepatic fibrosis biomarkers market, 2021 - 2033 (USD Million)
  • Fig. 50 Brazil Hepatic fibrosis biomarkers market, 2021 - 2033 (USD Million)
  • Fig. 51 Argentina Hepatic fibrosis biomarkers market, 2021 - 2033 (USD Million)
  • Fig. 52 MEA Hepatic fibrosis biomarkers market, 2021 - 2033 (USD Million)
  • Fig. 53 South Africa Hepatic fibrosis biomarkers market, 2021 - 2033 (USD Million)
  • Fig. 54 Saudi Arabia Hepatic fibrosis biomarkers market, 2021 - 2033 (USD Million)
  • Fig. 55 UAE Hepatic fibrosis biomarkers market, 2021 - 2033 (USD Million)
  • Fig. 56 Kuwait Hepatic fibrosis biomarkers market, 2021 - 2033 (USD Million)
  • Fig. 57 Strategy framework